John-David Aubert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1847800/publications.pdf

Version: 2024-02-01

201674 2,663 85 27 citations h-index papers

49 g-index 89 89 89 3839 docs citations times ranked citing authors all docs

197818

#	Article	IF	CITATIONS
1	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respiratory Medicine,the, 2017, 5, 785-794.	10.7	201
2	Chronic Rhinoviral Infection in Lung Transplant Recipients. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 1392-1399.	5 . 6	192
3	New Respiratory Enterovirus and Recombinant Rhinoviruses among Circulating Picornaviruses. Emerging Infectious Diseases, 2009, 15, 719-726.	4.3	130
4	Transforming growth factor beta 1 gene expression in human airways Thorax, 1994, 49, 225-232.	5.6	115
5	Respiratory viruses in bronchoalveolar lavage: a hospital-based cohort study in adults. Thorax, 2009, 64, 399-404.	5.6	105
6	Chronic Lung Allograft Dysfunction. Transplantation, 2016, 100, 1803-1814.	1.0	102
7	Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: Results of a prospective, randomized international trial in lung transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 797-804.	0.6	100
8	Airway Microbiota Determines Innate Cell Inflammatory or Tissue Remodeling Profiles in Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1252-1263.	5.6	99
9	Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenetics and Genomics, 2008, 18, 307-315.	1.5	82
10	Clinical outcomes of lung transplant recipients with telomerase mutations. Journal of Heart and Lung Transplantation, 2015, 34, 1318-1324.	0.6	82
11	Long-Term Data from the Swiss Pulmonary Hypertension Registry. Respiration, 2015, 89, 127-140.	2.6	72
12	<i>Protochlamydianaegleriophila</i> as Etiologic Agent of Pneumonia. Emerging Infectious Diseases, 2008, 14, 168-172.	4.3	64
13	CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients. Therapeutic Drug Monitoring, 2008, 30, 689-699.	2.0	63
14	Closure of large intrathoracic airway defects using extrathoracic muscle flaps. Annals of Thoracic Surgery, 2004, 77, 397-404.	1.3	61
15	Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism. European Respiratory Journal, 2018, 51, 1702505.	6.7	58
16	Burden of severe RSV disease among immunocompromised children and adults: a 10Âyear retrospective study. BMC Infectious Diseases, 2018, 18, 111.	2.9	55
17	Rhinovirus Genome Variation during Chronic Upper and Lower Respiratory Tract Infections. PLoS ONE, 2011, 6, e21163.	2.5	52
18	Negative Pressure Post-Tracheal Extubation Alveolar Hemorrhage. Anesthesia and Analgesia, 2001, 92, 273-275.	2.2	50

#	Article	IF	CITATIONS
19	Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung. Journal of Allergy and Clinical Immunology, 2018, 141, 718-729.e7.	2.9	49
20	Low-dose intradermal versus intramuscular trivalent inactivated seasonal influenza vaccine in lung transplant recipients. Journal of Heart and Lung Transplantation, 2011, 30, 679-684.	0.6	46
21	Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Medical Weekly, 2008, 138, 379-84.	1.6	43
22	Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Medical Weekly, 2007, 137, 573-80.	1.6	42
23	Respiratory viruses in HIV-infected patients with suspected respiratory opportunistic infection. Aids, 2008, 22, 701-705.	2.2	41
24	Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: Dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting) Tj ETQq0 0	0 r gB T /O	verløgck 10 Tf
25	The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with uterovaginal prolapse. American Journal of Obstetrics and Gynecology, 2005, 192, 426-432.	1.3	39
26	Incidence and Risk Factors of Abdominal Complications After Lung Transplantation. World Journal of Surgery, 2015, 39, 2274-2281.	1.6	36
27	Chronic norovirus gastroenteritis in a double hematopoietic stem cell and lung transplant recipient. Transplant Infectious Disease, 2011, 13, 213-215.	1.7	33
28	A prevalent and culturable microbiota links ecological balance to clinical stability of the human lung after transplantation. Nature Communications, 2021, 12, 2126.	12.8	31
29	Pulmonary involvement in Fabry disease: Overview and perspectives. European Journal of Internal Medicine, 2013, 24, 707-713.	2.2	27
30	Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis. Journal of Medicinal Chemistry, 2016, 59, 8168-8188.	6.4	27
31	Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Medical Weekly, 2008, 138, 371-8.	1.6	27
32	Lung transplantation after allogeneic stem cell transplantation: a pan-European experience. European Respiratory Journal, 2018, 51, 1701330.	6.7	26
33	Expression of \hat{I}^2 2-adrenergic Receptor mRNA in Peripheral Lung in Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 325-333.	2.9	24
34	Radiological findings of complications after lung transplantation. Insights Into Imaging, 2018, 9, 709-719.	3.4	24
35	Comparison of Three Antigenic Extracts of <i>Eurotium amstelodami</i> in Serological Diagnosis of Farmer's Lung Disease. Vaccine Journal, 2010, 17, 160-167.	3.1	23
36	Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. Journal of Heart and Lung Transplantation, 2010, 29, 299-305.	0.6	23

#	Article	IF	Citations
37	Role of rhinovirus load in the upper respiratory tract and severity of symptoms in lung transplant recipients. Journal of Clinical Virology, 2015, 64, 1-5.	3.1	23
38	Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study. American Journal of Transplantation, 2021, 21, 1789-1800.	4.7	23
39	Induction of Tumor Necrosis Factor Alpha and Interleukin-8 Gene Expression in Bronchial Epithelial Cells by Toxic Shock Syndrome Toxin 1. Infection and Immunity, 2000, 68, 120-124.	2.2	21
40	Acute Antibody-mediated Rejection 1 Week After Lung Transplantation Successfully Treated With Eculizumab, Intravenous Immunoglobulins, and Rituximab. Transplantation, 2018, 102, e301-e303.	1.0	19
41	Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. Journal of Medicinal Chemistry, 2018, 61, 9811-9840.	6.4	18
42	Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients with Valganciclovir. American Journal of Transplantation, 2005, 5, 1781-1782.	4.7	16
43	Ten years of lung transplantation in Switzerland: results of the Swiss Lung Transplant Registry. Swiss Medical Weekly, 2004, 134, 18-23.	1.6	16
44	Influenza vaccination and humoral alloimmunity in solid organ transplant recipients. Transplant International, 2014, 27, 903-908.	1.6	15
45	Clinical significance of postâ€prophylaxis cytomegalovirus infection in lung transplant recipients. Transplant Infectious Disease, 2018, 20, e12893.	1.7	15
46	First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. European Respiratory Journal, 2018, 51, 1701694.	6.7	15
47	Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials. Expert Opinion on Therapeutic Targets, 2009, 13, 1069-1084.	3.4	14
48	Pulmonary Hypertension and Indicators of Right Ventricular Function. Frontiers in Medicine, 2016, 3, 23.	2.6	14
49	Outcome after extracorporeal membrane oxygenation-bridged lung retransplants: a single-centre experience. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 922-928.	1.1	11
50	European survey on the management of tuberculosis in solid-organ transplant recipients and candidates. Transplant International, 2013, 26, e69-e70.	1.6	10
51	Human Bronchial Epithelial Cells Induce CD141/CD123/DC-SIGN/FLT3 Monocytes That Promote Allogeneic Th17 Differentiation. Frontiers in Immunology, 2017, 8, 447.	4.8	10
52	Bronchial anastomosis dehiscence and stenosis caused by donorâ€transmitted <i>Mycoplasma hominis</i> infection in a lung transplant recipient: Case report and literature review. Transplant Infectious Disease, 2021, 23, e13475.	1.7	10
53	Emotions while awaiting lung transplantation: A comprehensive qualitative analysis. Health Psychology Open, 2014, 1, 205510291456127.	1.4	9
54	Microbial Communities of Conducting and Respiratory Zones of Lung-Transplanted Patients. Frontiers in Microbiology, 2016, 7, 1749.	3.5	9

#	Article	IF	CITATIONS
55	Challenges in lung transplantation. Swiss Medical Weekly, 2011, 141, w13292.	1.6	9
56	Biochemical markers in the management of pulmonary hypertension. Swiss Medical Weekly, 2005, 135, 43-9.	1.6	9
57	Mycosis Fungoides in a Lung Transplant Recipient with Advanced Ciclosporin Nephropathy: Management with Mechlorethamine and Subsequent Renal Transplantation. Dermatology, 2008, 217, 87-88.	2.1	8
58	Management of Severe Portopulmonary Hypertension With Dual Oral Therapy Before Liver Transplantation. Transplantation, 2018, 102, e194.	1.0	8
59	Real-life food-safety behavior and incidence of foodborne infections in solid organ transplant recipients. American Journal of Transplantation, 2020, 20, 1424-1430.	4.7	8
60	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2015, 46, 1849-1851.	6.7	7
61	Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry. Pulmonary Circulation, 2022, 12, e12001.	1.7	7
62	Magnetic resonance imaging in pulmonary hypertension: an overview of current applications and future perspectives., 2022, 152, w30055.		7
63	Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 132.	2.4	6
64	Successful Bilateral Lung Transplantation After Previous Pneumonectomy. Annals of Thoracic Surgery, 2011, 91, 1302-1304.	1.3	4
65	Transcatheter Aortic Valve Implantation in a Lung TransplantÂRecipient. Annals of Thoracic Surgery, 2014, 97, e159-e160.	1.3	4
66	Granulomatous Reaction to <i>Pneumocystis jirovecii</i> Diagnosed in a Bronchoalveolar Lavage: A Case Report. Acta Cytologica, 2015, 59, 284-288.	1.3	4
67	Peak VO ₂ in Obesity: Is It Worth the Effort?. Respiration, 2017, 94, 486-487.	2.6	4
68	Secondary pulmonary alveolar proteinosis treated by lung transplant: A case report. Respiratory Medicine Case Reports, 2020, 30, 101108.	0.4	3
69	Pulmonary angioplasty: A step further in the continuously changing landscape of chronic thromboembolic pulmonary hypertension management. European Journal of Radiology, 2021, 136, 109562.	2.6	3
70	Extended-criteria donors in lung transplantation in Switzerland: an evaluation of two adapted lung donor scores. Swiss Medical Weekly, 2018, 148, w14614.	1.6	3
71	<i>Pseudomonas aeruginosa</i> biofilms in a bronchoalveolar lavage. Diagnostic Cytopathology, 2009, 37, 825-825.	1.0	2
72	Management of bilateral necrotizing bronchial dehiscence after a double lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, e29-e31.	0.8	2

#	Article	IF	Citations
73	Eculizumab and Intravenous Immunoglobulins for the Treatment of Acute Antibody-Mediated Rejection after Lung and Liver Transplantation. Transplantation, 2018, 102, S606.	1.0	2
74	Risk factors for chronic lung allograft dysfunction (CLAD) in the SysCLAD cohort. , 2015, , .		2
75	Comparison of Risk Stratification Scores in Pulmonary Arterial Hypertension: A Monocentric Retrospective Study at Lausanne University Hospital. Respiration, 2022, 101, 565-576.	2.6	2
76	Simple equations to predict the effects of venoâ€venous ECMO in decompensated Eisenmenger syndrome. ESC Heart Failure, 2021, 8, 1637-1642.	3.1	1
77	Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). , 2017, , .		1
78	Alveolar macrophages and pulmonary microbiota are interconnected indicators of lung ecology post-transplantation. , 2015, , .		1
79	SARS-CoV-2 / COVID-19 in patients on the Swiss national transplant waiting list. Swiss Medical Weekly, 2020, 150, w20451.	1.6	1
80	Complications of Valve Lung Volume Reduction in a Case ofÂPrevious Pleurodesis. Annals of Thoracic Surgery, 2014, 98, e71-e72.	1.3	0
81	A 58-Year-Old Man With Position-Dependent Nocturnal Dyspnea. Chest, 2017, 152, e51-e55.	0.8	0
82	Current management of pulmonary arterial hypertension. Swiss Medical Weekly, 2016, 146, w14305.	1.6	0
83	Open access bronchoscopy atlas: An online educational tool for pulmonologists. , 2016, , .		0
84	Evaluation of a lung donor score: retrospective analysis of Swiss donor data., 2017,,.		0
85	Compromised immunity and the microbiome: transplantation, cancer and HIV., 2019, , 195-215.		O